NYSE$CNC
Centene Corp · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Centene's second quarter performance in 2020 was solid, aligning with expectations as the company benefited from lower medical utilization due to the COVID-19 pandemic and executed well in a challenging environment.
Centene Corporation reported a strong second quarter in 2020, with diluted EPS of $2.05 and adjusted diluted EPS of $2.40. The company's performance was driven by lower medical utilization due to the COVID-19 pandemic and solid execution by the team. Total revenues increased by 51% compared to the second quarter of 2019, reaching $27.7 billion.
- Managed care membership reached 24.6 million, a 64% increase over the prior year.
- Total revenues grew by 51% to $27.7 billion compared to Q2 2019.
- The health benefits ratio (HBR) was 82.1%, compared to 86.7% in the prior year.
- Operating cash flow was $3.7 billion, representing 3.1x net earnings.
Headline financials
Revenue & EPS history
Centene · Revenue · Quarterly
$27.7B
Revenue by segment
Centene · $27B total across 4 segments · Q2 2020
- Medicaid$18.1B+49.6%67.1%
- Commercial$4.14B+6.8%15.3%
- Medicare$3.54B+141.5%13.1%
- Other$1.24B+37.2%4.6%
Forward guidance
Centene provided its annual guidance for 2020.
Tailwinds
- Total revenues are expected to be between $109.0 billion and $111.4 billion.
- GAAP diluted EPS is projected to be between $3.04 and $3.18.
- Adjusted Diluted EPS is expected to be between $4.76 and $4.96.
- Diluted shares outstanding are estimated to be between 577.9 million and 580.9 million.
- The company is well-positioned to respond quickly to evolving dynamics as it executes on its growth strategy, further supported by the strength of its balance sheet and solid financial position.
Headwinds
- Adjusted Diluted EPS excludes estimated amortization of acquired intangible assets of $0.98 to $1.00 per diluted share.
- Adjusted Diluted EPS excludes acquisition-related expenses of $0.67 to $0.71 per diluted share.
- Adjusted Diluted EPS excludes the gain on the sale of the Illinois health plan of approximately $0.10 per diluted share.
- Adjusted Diluted EPS excludes debt extinguishment costs of approximately $0.07 per diluted share.
- Adjusted Diluted EPS excludes non-cash asset impairment of $0.10 per diluted share.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
+0.4%
Avg return
Earnings day
+0.4%
Avg return
5 days after
+1.9%
Avg return
30 days after
54%
37 / 68 earnings
Positive
+13.8%
Q1 2014
Best reaction
-10.4%
Q2 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.5% | +22.6% | +33.9% | |
| Q4 2025 | -3.7% | +1.3% | +9.3% | |
| Q3 2025 | +12.5% | +3.9% | +18.5% | |
| Q1 2025 | -6.3% | -2.8% | -8.4% | |
| Q4 2024 | -5.4% | -9.1% | -8.3% | |
| Q3 2024 | +0.0% | +0.3% | -2.0% | |
| Q2 2024 | +9.0% | +14.1% | +16.5% | |
| Q1 2024 | -2.4% | -4.5% | -1.4% | |
| Q4 2023 | +1.1% | +4.4% | +7.5% | |
| Q3 2023 | -3.0% | -4.8% | +4.7% | |
| Q2 2023 | -2.7% | -3.7% | -9.2% | |
| Q1 2023 | -1.5% | +1.9% | -6.3% | |
| Q4 2022 | +2.7% | +2.4% | -7.7% | |
| Q3 2022 | +11.9% | +13.2% | +10.3% | |
| Q2 2022 | +0.6% | +1.1% | +4.1% | |
| Q1 2022 | -4.9% | -5.1% | -3.5% | |
| Q4 2021 | +6.4% | +3.1% | +4.5% | |
| Q3 2021 | +3.8% | +4.8% | +11.2% | |
| Q2 2021 | -4.0% | -5.6% | -12.5% | |
| Q1 2021 | -9.9% | -6.5% | +11.7% | |
| Q4 2020 | +4.8% | +1.6% | +6.3% | |
| Q3 2020 | -7.9% | -11.0% | -6.3% | |
| Q2 2020 | -1.4% | -3.0% | -10.1% | |
| Q1 2020 | -6.6% | -8.3% | -5.5% | |
| Q4 2019 | +5.1% | +0.4% | -5.0% | |
| Q3 2019 | +5.7% | +5.4% | +30.4% | |
| Q2 2019 | +3.0% | +2.4% | -12.7% | |
| Q1 2019 | +4.4% | +9.5% | +15.3% | |
| Q4 2018 | -2.9% | -3.2% | -13.2% | |
| Q3 2018 | -8.3% | -9.9% | -5.5% | |
| Q2 2018 | -3.1% | -3.0% | +6.0% | |
| Q1 2018 | -1.2% | -0.4% | +5.5% | |
| Q4 2017 | +5.0% | +2.3% | +0.9% | |
| Q3 2017 | -7.4% | -3.7% | -1.1% | |
| Q2 2017 | -1.0% | -1.8% | +2.1% | |
| Q1 2017 | +1.1% | +3.3% | +4.5% | |
| Q4 2016 | +7.9% | +9.1% | +9.3% | |
| Q3 2016 | +1.4% | +0.1% | -10.5% | |
| Q2 2016 | -10.4% | -6.3% | -10.0% | |
| Q1 2016 | +4.2% | — | — | |
| Q4 2015 | +2.2% | — | — | |
| Q3 2015 | +5.3% | — | — | |
| Q2 2015 | +0.2% | — | — | |
| Q1 2015 | -9.7% | — | — | |
| Q4 2014 | +5.6% | — | — | |
| Q3 2014 | +9.3% | — | — | |
| Q2 2014 | +5.8% | — | — | |
| Q1 2014 | +13.8% | — | — | |
| Q4 2013 | +4.5% | — | — | |
| Q3 2013 | -4.1% | — | — | |
| Q2 2013 | +5.1% | — | — | |
| Q1 2013 | +4.4% | — | — | |
| Q4 2012 | +6.1% | — | — | |
| Q3 2012 | +0.3% | — | — | |
| Q2 2012 | +6.9% | — | — | |
| Q1 2012 | -6.0% | — | — | |
| Q4 2011 | -2.5% | — | — | |
| Q3 2011 | +12.6% | — | — | |
| Q2 2011 | +3.3% | — | — | |
| Q1 2010 | +10.9% | — | — | |
| Q1 2011 | +2.4% | — | — | |
| Q4 2008 | -6.5% | — | — | |
| Q4 2010 | -6.5% | — | — | |
| Q3 2009 | -6.6% | — | — | |
| Q2 2009 | -6.6% | — | — | |
| Q3 2010 | -6.6% | — | — | |
| Q4 2009 | -5.3% | — | — | |
| Q2 2010 | -5.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro